Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1083-1091, 2009. First published April 16, 2009; 10.1373/clinchem.2008.120220
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.120220v1
55/6/1083    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Bickmann, J. K.
Right arrow Articles by Rossmann, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bickmann, J. K.
Right arrow Articles by Rossmann, H.
(Clinical Chemistry. 2009;55:1083-1091.)
© 2009 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

A Novel Approach to CFTR Mutation Testing by Pyrosequencing-Based Assay Panels Adapted to Ethnicities

Julia K. Bickmann1, Wolfgang Kamin2, Matthias Wiebel3, Friederike Häuser1, Jürgen J. Wenzel1, Carolin Neukirch1, Manfred Stuhrmann4, Karl J. Lackner1 and Heidi Rossmann1,a

1 Department of Clinical Chemistry and Laboratory Medicine, and 2 CF Center of the Children’s Hospital, Johannes Gutenberg University Mainz, Mainz, Germany; 3 Department of Pulmonology, Thorax Clinic of the University Clinic of Heidelberg, Heidelberg, Germany; 4 Institute of Human Genetics, Medical School, Hannover, Germany.

aAddress correspondence to this author at: Department of Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. Fax +49-6131-17-6627; e-mail rossmann{at}zentrallabor.klinik.uni-mainz.de.

Background: Cystic fibrosis (CF) is a common autosomal recessive genetic disorder caused by a variety of sequence alterations in the CFTR gene [cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)]. Because the relative prevalence of mutations strongly depends on the ethnic background, first-level testing of CF as defined by recent consensus recommendations ought to be adaptable to the ethnicity of patients.

Methods: We therefore developed and implemented a diagnostic approach to first-level testing for CF based on published mutation frequencies and Pyrosequencing (PSQ) technology that we complemented with standard procedures of mutation detection at the second level.

Results: The current test system of PSQ assays for 46 target CF mutations [including CFTRdele2,3 (21 kb) and 1342-6 (T)n (5T/7T/9T)] permits recombinations of single assays to optimize sensitivities for certain ethnicities. By easy expansion of the original mutation panel, the first-level test sensitivities with other ethnic groups would be increased, provided that the mutation frequencies are known. The test was validated with our local, ethnically mixed, but mainly German population (155 patients). The mutation-detection rate for the 92 patients whose CF was confirmed by the sweat test was 89.0% for the patients of German descent (73 of the 92 patients) and 73.7% for the patients of any other origin (19 of the 92 patients). Ethnicity-adapted testing panels for our foreign CF patients would increase the sensitivities for the respective groups by approximately 5%.

Conclusions: PSQ-based genotyping is a reliable, convenient, highly flexible, and inexpensive alternative to conventional methods for first-level testing of CFTR, facilitating flexible adaptation of the analyzed mutation panel to any local ethnic group.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.